title: Eruptive Nevi Mimicking Wart-Like Lesions under Selective BRAF Inhibition in a 37-Year-Old Female Melanoma Patient.
abstract: BACKGROUND
  The BRAF inhibitor vemurafenib is state of the art in therapy of patients with malignant melanoma in non-resectable stage III or stage IV and evidence of oncogenetic BRAF mutation. Multiple cutaneous side effects like rash and keratoacanthoma-like lesions have been described so far.
  
  
  METHODS
  We report a patient who presented multiple wart-like lesions under therapy with vemurafenib. Histologically we have seen multiple melanocytic nevi with a wart-like appearance. One melanoma in situ developed on the left forearm.
  
  
  CONCLUSIONS
  Eruptive nevi and induction of melanoma may be a further side effect in patients undergoing a therapy with BRAF inhibitors.
authors.affiliation: Department of Dermatology, Klinikum Ludwigshafen, Ludwigshafen am Rhein, Germany.
authors.forename: Laurenz
authors.initials: L
authors.lastname: Schmitt
authors.forename: Tamara
authors.initials: T
authors.lastname: Schumann
authors.forename: Oliver
authors.initials: O
authors.lastname: Inhoff
authors.forename: Christoph
authors.initials: C
authors.lastname: Löser
authors.forename: Martin
authors.initials: M
authors.lastname: Rebel
authors.forename: Edgar
authors.initials: E
authors.lastname: Dippel
keywords: BRAF inhibitor; Eruptive nevi; Melanoma; Melanoma in situ; Side effects; Vemurafenib; Wart-like lesions; Zelboraf